Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for NPC with Detectable EBV DNA
NCT03544099Phase 2Terminated
- Sponsor
- National Health Research Institutes
- Start
- May 2019
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in nasopharyngeal carcinoma (NPC), sponsored by National Health Research Institutes. Started May 2019; status: terminated.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03544099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03544099.